重塑免疫治療 漢衛眾人健康

Reimagining Immunotherapy for Patients Worldwide

Our Possibility

我們的可能性
研發專案
8 +
專利申請
150 +
進入臨床IND階段
最快
2.3 年
2025年的研發投資金額
5.48 億元
FBDB™
技術平台的核心優勢

結合先天性及適應性免疫系統 多管齊下攻擊腫瘤細胞
阻斷 SIRPα / CD47 訊號傳遞
阻斷 PD-1 / PD-L1訊號傳遞
改善腫瘤微環境或進一步激活巨噬細胞/T細胞

News

最新消息
漢康生技 HCB301 臨床進展說明
漢康生技 HCB301 臨床進展說明:與 FDA 共同重視病患安全,積極優化臨床方案,持續展現創新免疫療法潛力 […]
11 月 18, 2026
Read more
漢康生技榮獲115年度「國家藥物科技研究發展獎」銀質獎 HCB101創新免疫治療研發成果獲國家級肯定 HanchorBio Receives Silver Award at the 2026 National Pharmaceutical Technology and Research Development Award, Recognizing HCB101’s Innovative Immunotherapy Development
HanchorBio announced that its proprietary investigational immunotherapy candidate HCB101 has received the Silver Award at the 2026 National Pharmaceutical Technology and Research Development Award (NPRDA), jointly organized by Taiwan's Ministry of Health and Welfare and Ministry of Economic Affairs. The recognition highlights HanchorBio's achievements in innovative drug development, differentiated mechanisms of action, and clinical translational research. The award ceremony was held at the National Biotechnology Research Park in Taipei, Taiwan.
11 月 18, 2026
Read more
致漢康生技全體股東的一封信
致漢康生技全體股東的一封信   親愛的股東朋友們,大家好: 漢康生技一路走來,我與團隊多年來全心投入 […]
11 月 16, 2026
Read more
漢康生技於癌症免疫治療學會年會展現巨噬細胞導向免疫療法進展 發表臨床進度與新一代三特異性創新技術 HanchorBio Advances Macrophage-Directed Immunotherapy at SITC 2026, Highlighting Clinical Progress and Next-Generation Trispecific Innovation
HanchorBio highlighted findings from four scientific presentations at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. The presentations demonstrated progress across HanchorBio’s clinical and preclinical pipeline, reinforcing its strategy to advance cancer immunotherapy beyond individual checkpoints through coordinated innate and adaptive immune modulation.
11 月 09, 2026
Read more
漢康生技攜手高醫簽署合作備忘錄 深化癌症臨床研究合作 HanchorBio and Kaohsiung Medical University Hospital Sign MOU to Strengthen Cancer Clinical Research Collaboration
HanchorBio announced the signing of a Memorandum of Understanding (MOU) with Kaohsiung Medical University Hospital (KMUH). The collaboration combines HanchorBio's expertise in innovative drug development and clinical development with KMUH's clinical and research expertise in gastrointestinal oncology to explore potential opportunities for future clinical research. Both parties aim to generate additional scientific evidence in cancer research through clinical studies, while maintaining rigorous standards of patient safety, medical ethics, and regulatory compliance.
11 月 05, 2026
Read more
漢康生技 HCB303 採差異化 TIGIT-Fc 策略 繼美國 FDA 後再獲台灣 TFDA 核准臨床試驗 Beyond Conventional Anti-TIGIT: HanchorBio Secures Taiwan TFDA Approval for HCB303 Following U.S. FDA Clearance
HanchorBio announced that its wholly owned subsidiary, FBD Biologics Limited, has received approval from the Taiwan Food and Drug Administration (TFDA) for the Investigational New Drug (IND) application for HCB303, a next-generation trispecific fusion protein featuring a differentiated TIGIT-Fc ligand-trap strategy.
10 月 30, 2026
Read more
漢康生技四篇科學摘要獲 ESMO 2026 年會接受 展現差異化免疫治療研發策略 HanchorBio Announces Acceptance of Four Scientific Abstracts for ESMO Congress 2026, Highlighting Differentiated Immunotherapy Strategy
HanchorBio announced that four scientific abstracts covering HCB101 and HCB301 were accepted for ESMO Congress 2026, taking place October 23–27 in Madrid, Spain.
10 月 27, 2026
Read more
漢康-KY於 BIO-Europe 2026 推進 HCB101 全球策略合作機會 HanchorBio Advances HCB101 Global Partnering Opportunities at BIO-Europe 2026
HanchorBio announced its participation in BIO-Europe 2026, taking place November 9–11 in Cologne, Germany.
10 月 27, 2026
Read more
漢康生技攜手 Aston Sci 展開策略合作 結合癌症疫苗與次世代免疫療法,探索創新聯合治療潛力 HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations
HanchorBio and Aston Sci today announced a strategic research collaboration to evaluate novel combination therapies joining HanchorBio's HCB101 macrophage-directed immunotherapy with Aston Sci's therapeutic cancer vaccine candidates.
10 月 22, 2026
Read more
漢康生技召開科學顧問委員會議 HCB101 臨床進展與 FDA 共識支持邁向全球註冊性臨床開發 HanchorBio Advances HCB101 Toward Global Registrational Development Following SAB Review and FDA Alignment
HanchorBio announced outcomes from its latest Scientific Advisory Board (SAB) meeting. Highlights included significant clinical progress for its lead asset, HCB101; alignment with the U.S. FDA on a registrational pathway in second-line gastric/ gastroesophageal junction (GC/GEJ) cancer; and continued expansion of the company’s research pipeline across oncology and immune-mediated diseases.
10 月 19, 2026
Read more

Investor Center

投資人專區
股東專區
財務專區
投資問與答
JOIN OUR TEAM

關於漢康

Advancing science, expanding hope.
我們無懼探索,只為拓展生命的可能